tirzepatide and creatine – Research Peptide How Creatine & GLP-1 Support

Clinical trials running up to 72 weeks have shown a manageable safety profile with primarily GI-related side effects

Treatment should be discontinued after 2 years or earlier if a 5% reduction in body weight is not achieved after 6 months at the maintenance dose

This is one of the most compelling arguments in tirzepatide's favor beyond simple weight loss numbers

"We are excited to share that the Zepbound single-dose vials are now here, further delivering on our promise to increase supply of Zepbound in the US," said Patrik Jonsson, executive vice president, and president of Lilly Cardiometabolic Health and Lilly USA